Biogen 因超说明书推广 GLP-1 药物被调查
STAT+: Most-favored nations policy makes drugmakers rethink launches abroad
Biogen 因推广其 GLP-1 药物 Mounjaro 作为减肥治疗而受到调查,一名前 Eli Lilly 销售代表指控公司未经批准即进行推广并因此被解雇。
Biogen under investigation, lawsuits over off-label GLP-1 promotion, and more biotech news
![]()
Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning. Thanksgiving is approaching and I’ve yet to make an all-butter pie crust that doesn’t shrink. Any tips or suggestions appreciated!
A former Eli Lilly sales rep filed a lawsuit alleging that she was fired after complaining that the company promoted its Mounjaro diabetes drug as a weight loss treatment before receiving regulatory approval to do so.
STAT+ Exclusive Story
Already have an account? Log in

This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
-
National Biotech Reporter
Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.
来源:STAT Pharma 医药频道 · statnews.com